<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003815</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066967</org_study_id>
    <secondary_id>SNLG-NHL-Va</secondary_id>
    <secondary_id>EU-98032</secondary_id>
    <nct_id>NCT00003815</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scotland and Newcastle Lymphoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer
      cells. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy
      drugs and kill more cancer cells.

      PURPOSE: Randomized phase III trial to study the effectiveness of chemotherapy and radiation
      therapy plus bone marrow transplantation in treating patients who have aggressive
      non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Assess the rate of remission in patients with aggressive non-Hodgkin's lymphoma treated
           with high-dose chemotherapy and radiotherapy plus autologous bone marrow
           transplantation.

        -  Determine the efficacy and toxic effects of this regimen in these patients.

      OUTLINE: This is a randomized, placebo-controlled, multicenter study. Patients are stratified
      according to risk group (good vs intermediate vs poor).

      Patients undergo harvest of autologous bone marrow stem cells after priming chemotherapy and
      before transplantation.

      Patients receive induction chemotherapy comprising the CHOP or VAPEC-B regimen. The CHOP
      regimen consists of vincristine (VCR) IV, cyclophosphamide (CTX) IV, and doxorubicin (DOX) IV
      on day 1 and oral prednisolone (PRDL) on days 1-5. Treatment repeats every 3 weeks for six
      courses. The VAPEC-B regimen consists of DOX IV on days 1, 15, 29, 43, 57, and 71; CTX IV on
      days 1, 29, and 57; VCR IV on days 8, 22, 36, 50, and 64; bleomycin IV on days 8, 36, 64;
      oral etoposide (VP-16) on days 15-19, 43-47, and 71-75; and oral PRDL daily for 13 weeks.

      Patients then may undergo radiotherapy for 2-3 weeks to areas of original bulk or residual
      disease.

        -  Good-risk group: Patients are randomized to one of two treatment arms.

             -  Arm I: Patients receive no further treatment.

             -  Arm II: Patients receive melphalan (L-PAM) before or after total body irradiation
                (TBI), which is delivered in 3 fractions over 24 hours. After completion of
                radiotherapy, patients undergo autologous bone marrow transplantation (AuBMT).

        -  Intermediate- or poor-risk group: Patients are randomized one of three treatment arms.

             -  Arm III: Patients receive L-PAM IV on day -2 and AuBMT on day 0.

             -  Arm IV: Patients receive treatment as in arm II.

             -  Arm V: Patients receive carmustine IV on day -6, VP-16 IV once daily and cytarabine
                IV twice daily on days -5 to -2, and L-PAM IV on day -1. Radiotherapy to bulk
                disease begins after completion of chemotherapy. Patients undergo AuBMT on day 0.

      Patients are followed monthly for 3 months, every 2 months for 1 year, every 4 months for 2
      years, and then every 6 months thereafter.

      PROJECTED ACCRUAL: Not specified
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 1994</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bleomycin sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed aggressive non-Hodgkin's lymphoma requiring chemotherapy

          -  Stage II, III, or IV

               -  B cell:

                    -  Centroblastic

                    -  Immunoblastic

                    -  Large cell anaplastic

                    -  Non-Burkitt lymphoblastic

               -  T cell:

                    -  Pleomorphic medium cell

                    -  Pleomorphic large cell

                    -  Immunoblastic

                    -  Large cell anaplastic

                    -  Lymphoblastic

                         -  No Burkitt (L3) subtype

                         -  No large mediastinal mass OR

          -  Stage I, II, III, or IV

               -  Bulk disease greater than 10 cm

               -  Nodal or extranodal site

          -  No primary localized gut lymphoma

          -  No CNS involvement

        PATIENT CHARACTERISTICS:

        Age:

          -  15 to 65

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  No concurrent bone marrow dysplastic syndromes

        Hepatic:

          -  Bilirubin no greater than 2.5 times upper limit of normal (ULN)

        Renal:

          -  Creatinine no greater than 2.5 times ULN

        Other:

          -  No other malignancy except skin cancer or stage I cervical cancer

          -  Not pregnant

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  See Disease Characteristics

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen J. Proctor, MD, FRCP, FRCPath</last_name>
    <role>Study Chair</role>
    <affiliation>Newcastle-upon-Tyne Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Newcastle Upon Tyne Hospitals NHS Trust</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2001</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>stage I adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage I adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

